Improving Efficacy of Diabetes Management Using Treatment Algorithms in a Mainly Hispanic Population

Table 2—

Treatment regimens at the end of 12 months

Medications CC-TA UC-TA CC-SC
n 106 170 82
Diabetes
 Initial treatment (100%)
  Glucotrol XL 96 (91) 167 (98) 48 (59)
  Chlorpropamide 0 0 9 (11)
  Glyburide 0 0 15 (18)
  Metformin 0 0 8 (10)
  Diet and exercise 10 (9) 3 (2) 2 (2)
 Final treatment (100%)
  Glucotrol XL 75 (71) 104 (61) 34 (42)
  Glucotrol XL/metformin 19 (18) 55 (32) 20 (25)
  Glucotrol XL/metformin + insulin 0 3 (2) 1 (1)
  Chlorpropamide 0 0 1 (1)
  Glyburide 0 0 6 (7)
  Metformin 0 0 13 (16)
  Insulin 0 0 2 (2)
  Diet and exercise 12 (11) 8 (5) 5 (6)
Hypertension
 Initial treatment (100%)
  Monopril 40 (38) 93 (55) 23 (28)
  Benazepril 0 0 6 (7)
  Captopril 0 0 2 (2)
  Diltiazem-SR 0 0 3 (4)
  Enalapril 0 0 7 (9)
  None 66 (62) 77 (45) 41 (50)
 Final treatment (100%)
  Monopril 37 (35) 79 (47) 24 (29)
  Monopril/diltiazem-SR 3 (3) 14 (8) 7 (9)
  Monopril/diltiazem/hydrochlorothiazide 0 0 4 (5)
  Vera pamil 0 0 2 (2)
  None 66 (62) 77 (45) 45 (55)
Dyslipidemia
 Initial treatment (100%)
  Pravastatin 31 (29) 29 (17) 2 (2)
  Gemfibrozil 7 (7) 16 (9) 9 (11)
  Simvastatin 0 0 4 (6)
  Lovastatin 0 0 2 (2)
  None 68 (64) 125 (74) 65 (79)
 Final treatment (100%)
  Pravastatin 31 (29) 29 (17) 2 (2)
  Gemfibrozil 8 (8) 16 (9) 7 (9)
  Simvastatin 0 0 3 (4)
  Lovastatin 0 0 2 (2)
  None 67 (63) 125 (74) 68 (83)
  • Data are n (%).

This Article

  1. Diabetes Care July 2004 vol. 27 no. 7 1638-1646